RedHeaderRight1

Current Articles | Archives | Search

Monday, November 16, 2020
Ambu ACTion Block Pain Pump Available to Intalere Members Through New Group Purchasing Agreement
By Andrea Inman @ 1:57 PM :: 214 Views :: Article Rating :: Agreements
 

Ambu ACTionTM Block Pain Pump Available to Intalere Members Through New Group Purchasing Agreement

Contact: Evan Danis
  Sr. Director, Corporate Communications
724-778-3423
evan.danis@intalere.com

St. Louis (November 16, 2020) – Intalere, the healthcare industry leader in delivering solutions designed for improved financial, operational and clinical health for our partners, announces a new agreement with Ambu, Inc. for pain care management solutions.

Through this agreement Intalere members will receive negotiated pricing on the Ambu® ACTionTM Block Pain Pump that provides a continuous, stable delivery of local anesthesia to the nerve block catheter and enables the anesthesiologist to tailor the infusion strategy to best match each individual patient’s unique pain needs throughout the course of treatment. The advanced technology of the non-electric ACTion Block CPNB Pump produces flow consistencies common to electrical pumps. 

This contract is currently effective through October 31, 2023.

About Ambu, Inc.
Millions of patients and healthcare professionals worldwide depend on the functionality and performance of Ambu products. Ambu is dedicated to improving patient safety and determined to advance single-use devices. The manifestations of Ambu’s efforts range from early inventions like the Ambu Bag™ resuscitator and the legendary BlueSensor™ electrodes to the newest landmark solutions like the aScope™ endoscope – the world’s first single-use flexible video scope. Ambu launched the world’s first single-use flexible bronchoscope, the Ambu® aScope™ in 2009. In 2019, over 600,000 Ambu single-use endoscopes were used in more than 6,000 hospitals making Ambu the world’s largest supplier of single-use endoscopes. In 2020, Ambu expects to sell over 1 million single-use endoscopes. Ambu received 510(k) clearance from the U.S. Food and Drug Administration in July 2020 for its single-use aScope™ Duodeno, and the FDA cleared Ambu’s aScope™ 4 Cysto in April 2020. By 2022, Ambu plans to introduce another 12 new devices across all major areas of endoscopy, including GI, the largest endoscopy market globally. Ambu’s commitment to bringing new ideas and superior service has made Ambu one of the most recognized medical companies in the world. Learn more at www.ambuusa.com

About Intalere
Intalere’s mission focuses on elevating the health of healthcare by designing solutions to improve our members’ financial, operational and clinical performance. We empower our customers and deliver measurable results through our highly personalized approach of creating strategies and programs focused on their goals. From managing their entire spend to strategic consulting around diagnosing particular areas of concern, our unique provider led model allows us to leverage nationally recognized best practices in supply chain and patient outcomes to drive efficiencies for our members. To learn more, visit www.intalere.com.

Rating
Comments

Illuminated-Path-Podcast-Support

Illuminated Path Podcast Series

Listen to healthcare leaders, thinkers and innovators lead enriching discussions about industry best practices related to elevating clinical, operational and financial performance.

Listen now


News

Newsroom

Intalere News Coverage

Intalere Blog

Press Releases

New Intalere Agreements

White Papers

Industry Experts

Event Calendar


Recent Blog Posts

Visit Our Blog